binding affinity News and Research

RSS

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

Exploring bioinformatics approach for evaluating binding affinities of probable COVID-19 therapeutic decoys

Researchers developed a computational workflow based on molecular dynamic (MD) simulations and artificial neural network (ANN) to assess the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD)-human angiotensin-converting enzyme 2 (hACE2) binding affinities of SARS-CoV-2 variants.

17 Jan 2023

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers evaluated the use of receptor decoys for SARS-CoV-2 based on soluble forms of ACE2 for immunological prophylaxis and management of COVID-19 through the use of AAV vectors.

16 Jan 2023

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Researchers discovered that the spike protein of SARS-CoV-2 is susceptible to cleavage at the disulfide bonds, and the vulnerability to reductive cleavage varies across variants, with the Omicron variant family being highly susceptible to reduction.

10 Jan 2023

Study shows XBB.1.5 exhibits a substantially higher hACE2-binding affinity compared to BQ.1.1 and XBB/XBB.1

Researchers investigated the reasons for the rapid advent of SARS-CoV-2 XBB.1.5, a sublineage of the Omicron recombinant mutant XBB in the USA.

6 Jan 2023

Study shows angiotensin-converting enzyme 2 decoy protein as a promising anti-SARS-CoV-2 agent

Researchers presented a microbody recombinant decoy protein with high affinity to angiotensin-converting enzyme 2 (ACE2) as an option for coronavirus disease 2019 (COVID-19) treatment.

5 Jan 2023

Scientists explore synthesis of griffithsin in cell-free systems

A new study described the cell-free manufacturing of griffithsin (GRFT), a broad-spectrum antiviral protein.

28 Dec 2022

Researchers present a new strategy for self-adjuvanting vaccine development

This new article publication from Acta Pharmaceutica Sinica B, discusses a fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development.

23 Dec 2022

Study identifies four new monoclonal antibodies with broad neutralizing potencies that target conserved SARS-CoV-2 epitopes

Researchers described four novel monoclonal antibodies with potent and broad neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the current globally dominant Omicron BA.4/BA.5.

20 Dec 2022

Scientists identify a novel epitope at the SARS-CoV-2 spike furin cleavage site

Scientists identify an immunogenic epitope at the furin cleavage site of the SARS-CoV-2 spike protein.

15 Dec 2022

Bioinformatics approach for the design of siRNAs against SARS-CoV-2

Scientists have developed a set of siRNAs against SARS-CoV-2 using computational approaches.

14 Dec 2022

Polymorphisms in human immunoglobulin heavy chain genes can influence the function of SARS-CoV-2 neutralizing antibodies

Researchers isolated SARS-CoV-2 spike protein-targeted mAbs from convalescent healthcare workers, emphasizing the IGHV1-69 gene, the gene with the greatest structural and allelic variation.

14 Dec 2022

Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection

Researchers compared the efficiency of bioengineered soluble ACE-2 concerning brain protection during COVID-19.

12 Dec 2022

SARS-CoV-1 and SARS-CoV-2 spike proteins utilize different mechanisms to bind to ACE2

Researchers apply computational approaches to study the binding mechanisms of the SARS-CoV-2 and SARS-CoV spike proteins to the ACE2 receptor.

11 Dec 2022

Researchers design novel compounds with potential as drug treatments for COVID-19

The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been devastating the entire world. While the vaccination program is advancing, drug treatments for COVID-19 are still highly important for those who become infected.

9 Dec 2022

Characterization of SARS-CoV-2 Omicron BQ.1.1

Researchers characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BQ.1.1 sub-variant.

9 Dec 2022

Novel prefusion S antigen designed by the mutation of the SARS-CoV-2 Spike protein’s trimeric structure

Researchers mutated the SARS-CoV-2 spike protein's trimeric structure to design a novel prefusion S antigen, S2D14.

1 Dec 2022

Fingerprint-embedding framework can help find novel drug candidates

Researchers have developed a new computer framework that holds promise in the work to discover new drugs. Their framework uses an artificial intelligence method called convolutional neural network to provide global information about potential novel drug candidates.

30 Nov 2022

The antibody resistance profile and viral receptor binding affinity of SARS-CoV-2 Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants

Researchers investigated the neutralizing antibody titers against the newly emergent BQ.1, BQ.1.1, XBB, and XBB.1 SARS-CoV-2 Omicron subvariants using sera from individuals with primary and booster COVID-19 vaccinations and previous SARS-CoV-2 infections.